Cover Image

Access to free DAAs for people who inject drugs: is it sufficient to increase the update of HCV treatment by PWIDs?

Saved in:

Bibliographic Details
Main Authors:	Maka Gogia (Author), Khatuna Kutateladze (Author), Keti Stvilia (Author), Irma Khonelidze (Author), Alexander Asatiani (Author)
Format:	Book
Published:	Elsevier, 2018-05-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Attitudes towards harm reduction/HIV counselling and testing services of sexual partners of People who inject drugs
by: Maka Gogia, et al.
Published: (2018)

Updated View on Kidney Transplant from HCV-Infected Donors and DAAs
by: Fabrizio Fabrizi, et al.
Published: (2021)

Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update
by: Hrvoje Roguljic, et al.
Published: (2021)

Virological impact of HCV elimination with DAAs in the HIV reservoir in HIV/HCV patients
by: M. Coiras, et al.
Published: (2019)

Anti-HCV DAA are needed whatever liver fibrosis is. The cons
by: Pablo Barreiro
Published: (2016)

Anti-HCV DAA are needed whatever liver fibrosis is. The pros
by: Albert Tran
Published: (2016)

O9 Progress towards elimination: rapid uptake of HCV treatment among people who inject drugs following broad access to DAA therapies
by: J. Iversen, et al.
Published: (2017)

P22 'No closed door' to HCV treatment in the era of fully funded DAAs: access to a peer navigator is essential
by: M.E. Harrod, et al.
Published: (2017)

O20 Opportunities and challenges experienced when treating HCV in people who inject drugs (PWID) through a nurse-led outreach model
by: K. Allardice, et al.
Published: (2017)

Hidden populations: risk behaviours in drug-using populations in the Republic of Georgia through subsequent peer-driven interventions
by: Cale Lawlor, et al.
Published: (2021)

P27 Hepatitis B outreach to people who inject drugs (PWID)
by: L. Kanaef
Published: (2017)

P28 Queensland injectors health network (QuIHN) treatment management program (TMP): hepatitis C virus (HCV) direct acting antivirals (DAA) full access for people who inject drugs
by: R. Kavanagh, et al.
Published: (2017)

O12 Australia could meet the WHO HCV elimination targets if the current rollout of DAA treatment is continued
by: A.J. Kwon, et al.
Published: (2017)

Harm reduction program and hepatitis C prevalence in people who inject drugs (PWID) in Iran: an updated systematic review and cumulative meta-analysis
by: Abdolhalim Rajabi, et al.
Published: (2021)

Barriers of linkage to HCV viremia testing among people who inject drugs in Georgia
by: Maia Butsashvili, et al.
Published: (2022)

People who inject drugs (PWID) and HIV/aids cases in Mexico City: 1987-2015
by: Martha Romero Mendoza, et al.
Published: (2019)

Efficacy of DAAs in the Treatment of Chronic HCV: Real-World Data from the Private Health-Care Sector of the Kingdom of Saudi Arabia
by: Almoutaz Hashim, et al.
Published: (2020)

The Mortality and its Related Factors among HIV Positive People Who Inject Drugs (PWID) in Malaysia.
by: Aida Roziana Ramlan, et al.
Published: (2022)

P29 Treating hepatitis C virus infection (HCV) with direct acting antivirals (DAAs) through the existing infrastructure of opioid agonist therapy (OAT)
by: J. Keats, et al.
Published: (2017)

O7 Moving towards HCV elimination in HIV/HCV co- infection in Australia following universal access to interferon-free therapy
by: Marianne Martinello, et al.
Published: (2017)

Stigmatization of people who inject drugs (PWID) by pharmacists in Tajikistan: sociocultural context and implications for a pharmacy-based prevention approach
by: Umedjon Ibragimov, et al.
Published: (2017)

Substance use, injection risk behaviors, and fentanyl-related overdose risk among a sample of PWID post-Hurricane Maria
by: Roberto Abadie, et al.
Published: (2022)

Navigating environmental constraints to injection preparation: the use of saliva and other alternatives to sterile water among unstably housed PWID in London
by: Magdalena Harris, et al.
Published: (2020)

Current trends in needle-free jet injection: an update
by: Barolet D, et al.
Published: (2018)

Epidemiological and economic evaluations according to DAA treatment access: an interim evaluation based on PITER cohort data
by: Stefano Vella, et al.
Published: (2018)

Rapid situational assessment of people who inject drugs (PWID) in Nairobi and coastal regions of Kenya: a respondent driven sampling survey
by: Francis O. Oguya, et al.
Published: (2021)

Correction: Substance use, injection risk behaviors, and fentanyl‑related overdose risk among a sample of PWID post‑Hurricane Maria
by: Roberto Abadie, et al.
Published: (2022)

Correction to: Navigating environmental constraints to injection preparation: the use of saliva and other alternatives to sterile water among unstably housed PWID in London
by: Magdalena Harris, et al.
Published: (2020)

Italian Real-World Analysis of the Impact of Polypharmacy and Aging on the Risk of Multiple Drug–Drug Interactions (DDIs) in HCV Patients Treated with Pangenotypic Direct-Acting Antivirals (pDAA)
by: Fagiuoli S, et al.
Published: (2023)

Pragmatic barriers for delay in access to HCV testing services: Perspective of People With Injecting Drugs and living with HIV
by: Varada Jayant Madge, et al.
Published: (2017)

HCV treatment access among Latinxs who inject drugs: qualitative findings from Boston, Massachusetts, 2016
by: Avni Mittal, et al.
Published: (2019)

Cross-sectional study of drug-use patterns (RADUP) to inform risk-reduction interventions for people who use/inject drugs (PWUD/PWID) in Sri Lanka
by: Sathya Herath, et al.
Published: (2018)

Management of Hepatitis C Infection with Direct Action Antiviral Drugs (DAA)**
by: Roberto Focaccia, et al.
Published: (2015)

The effect of APN, hs-CRP and APN/hs-CRP in periodontitis with DAA
by: Rui Cheng, et al.
Published: (2023)

Needle acquisition patterns, network risk and social capital among rural PWID in Puerto Rico
by: Ian Duncan, et al.
Published: (2017)

Hepatitis C virus infection: Epidemiology in Egypt, Pathophysiology and DAAs-based therapy
by: Heba Elbadawy, et al.
Published: (2021)

Equitable access to HCV care in HIV-HCV co-infection can be achieved despite barriers to health care provision
by: Curtis L Cooper, et al.
Published: (2010)

Baseline prevalence and correlates of HIV and HCV infection among people who inject drugs accessing a syringe services program; Miami, FL
by: Tyler S. Bartholomew, et al.
Published: (2020)

Injection partnership characteristics and HCV status associations with syringe and equipment sharing among people who inject drugs
by: Mary Ellen Mackesy-Amiti, et al.
Published: (2023)

HIV/HCV co-infection and associated risk factors among injecting drug users in Dar es Salaam, Tanzania: potential for HCV elimination
by: Germana Henry Leyna, et al.
Published: (2019)